GlassScriptPhysician profile
Joseph Myles Smith
NPI 1306919352
$32,512.51
in general payments reported to CMS, 2019-2025
10 companies · $32K in 2025
The $32K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.52 · 2020: $60.45 · 2021: $84.55 · 2022: $90.05 · 2023: $110 · 2024: $123 · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,905 · Travel and Lodging: $4,305 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,750 · Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $16,800.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,905.00 |
| Travel and Lodging | $4,304.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,750.00 |
| Food and Beverage | $1,491.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $21,439.10 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $8,797.75 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $1,750.00 | 2025 | Xelstrym |
| Corium, LLC | $145.92 | 2023-2024 | Azstarys |
| Amgen INC. | $120.88 | 2025 | Repatha |
| Ironshore Pharmaceuticals INC. | $91.96 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $84.39 | 2020-2024 | Dyanavel Xr |
| Pfizer INC. | $46.85 | 2021 | |
| Glaxosmithkline, LLC. | $19.79 | 2020 | |
| Merck Sharp & Dohme LLC | $15.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.